Emerging Infectious Diseases in Animals: Drivers, Detection, and Response

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Drivers of Emergence: Anthropogenic factors like land use change (deforestation, agricultural expansion), agricultural intensification (high stocking densities), wildlife trade, and climate shifts are primary drivers, increasing contact between wildlife reservoirs, domestic animals, and humans, facilitating pathogen spillover and amplification.
• Early Detection Strategies: Effective early detection relies on risk-based surveillance targeting wildlife-domestic animal-human interfaces, syndromic monitoring for unusual clinical patterns, and advanced molecular diagnostics (e.g., PCR, metagenomic sequencing) capable of identifying novel variants or unknown agents.
• Diagnostic Challenges: Investigating suspected emerging pathogens requires a structured, hypothesis-driven approach, moving beyond routine panels to consider metagenomic sequencing for unknown agents, paired serology for confirmation, and culture for antimicrobial susceptibility testing, acknowledging limitations like delayed diagnosis and cross-reactivity.
• Response Coordination: International frameworks from WOAH (animal health standards), WHO, and CDC (One Health frameworks) guide multisectoral response efforts, emphasizing the need for coordinated surveillance and collaboration between veterinary, public health, and environmental sectors for zoonotic disease control.
• Pathogen Characteristics: Emergence can involve known pathogens re-emerging (e.g., Leptospira due to ecological shifts) or novel agents crossing species barriers (e.g., Coronaviruses via spike protein mutations), with prion diseases presenting a distinct mechanism involving misfolded proteins.
• Biocontainment and Treatment: Infection control measures must be scaled to risk assessment, from standard precautions to enhanced biocontainment for high-risk pathogens, while antimicrobial stewardship is critical, necessitating sample collection before empirical therapy and narrowing spectrum based on susceptibility results.

Emerging infectious diseases in animals represent a persistent and accelerating challenge for veterinary medicine, public health, and agricultural systems worldwide. This article provides a structured analysis of the ecological and anthropogenic forces that drive disease emergence, the surveillance and diagnostic approaches used to detect novel pathogens, and the response frameworks available to veterinary professionals. It is written for veterinary researchers and clinicians who require a rigorous conceptual foundation for interpreting outbreak data, designing surveillance programs, and participating in multisectoral response efforts.

The scope is deliberately cross-species, encompassing companion animals, livestock, wildlife, and zoonotic pathogens that bridge animal and human populations. The article addresses three core questions: what conditions permit a pathogen to emerge or re-emerge in animal populations, how can veterinary professionals detect emergence early enough to intervene, and what response mechanisms exist at practice, institutional, and international levels. The evidence base draws on peer-reviewed reviews of specific disease systems, international standards from the World Organization for Animal Health, and frameworks published by the World Health Organization and the Centers for Disease Control and Prevention.

At a Glance

Conceptual Foundations of Disease Emergence

Emergence is not a single event but a process with identifiable stages: pathogen introduction into a new host population, establishment of transmission, and amplification to detectable levels. The transition from sporadic spillover to sustained transmission depends on pathogen traits, host susceptibility, and population density. For zoonotic agents, the process often begins in wildlife reservoirs, passes through domestic animal bridge hosts, and only later reaches human populations.

Leptospirosis illustrates how a well-characterized pathogen can re-emerge when ecological conditions shift. The epidemiology of leptospirosis has been modified by changes in animal husbandry, climate, and human behavior, and the disease is now classified among the emerging infectious diseases with substantially greater incidence in tropical regions. Large outbreaks have drawn renewed attention to the need for rapid diagnostic assays, particularly because early antibiotic therapy improves outcomes in acute disease. The leptospirosis model demonstrates that emergence can involve a known pathogen expanding its geographic range or transmission intensity instead of a genuinely novel agent.

Coronaviruses represent the opposite pattern, where previously low-pathogenicity viruses crossed species barriers and produced severe disease in new hosts. The severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus both originated as zoonotic infections, and their emergence highlighted the importance of controlling infectious pathogens at international borders. Research on these viruses has focused on the spike proteins that mediate host receptor binding and species affinity, because these molecular features determine which species can be infected and whether sustained transmission is possible.

Anthropogenic and Ecological Drivers

Land use change is the most consistent anthropogenic driver of emergence. Deforestation, agricultural expansion, and urban encroachment bring domestic animals and humans into contact with wildlife reservoirs that were previously geographically isolated. These interfaces create repeated opportunities for pathogen spillover, and the probability of establishment increases when domestic animal populations are dense and immunologically naive.

Agricultural intensification amplifies transmission once a pathogen enters a production system. High stocking densities, genetic uniformity, and frequent animal movement facilitate rapid spread. Changes in animal husbandry practices have been specifically implicated in the changing epidemiology of leptospirosis, and similar mechanisms apply to Campylobacter, where poultry production serves as a major reservoir and source of transmission to humans. The global epidemiology of campylobacteriosis shows increasing incidence in developed and developing countries alike, with emerging species such as Campylobacter concisus and Campylobacter ureolyticus gaining clinical recognition.

Climate acts as a modulating driver instead of a direct cause. Temperature and precipitation patterns affect vector distributions, pathogen survival in the environment, and wildlife host population dynamics. These effects are regionally heterogeneous, and predicting emergence from climate data alone remains unreliable. Wildlife trade and the international movement of animals provide additional pathways for pathogen introduction across geographic boundaries that would otherwise limit spread.

Host-Pathogen Dynamics and Species Barriers

Crossing the species barrier requires a pathogen to overcome multiple obstacles: cellular receptors must be compatible, innate immune responses must be evaded or tolerated, and within-host replication must reach levels sufficient for onward transmission. The coronavirus spike protein studies demonstrate that small numbers of amino acid changes can alter receptor binding affinity and expand host range. These molecular determinants are now a focus of pre-emergence risk assessment, because surveillance can target pathogens with known receptor compatibility for high-value host species.

Prion diseases present a distinct emergence mechanism. The transmissible spongiform encephalopathies involve misfolded protein aggregates instead of conventional infectious agents, and the relationship between protein aggregation and neurotoxicity remains incompletely understood. Research suggests that prefibrillar oligomers or protofibrils may be the primary neurotoxic species, while the fibrillar aggregates observed at autopsy may represent a protective or bystander phenomenon. This distinction matters for surveillance because diagnostic tests that detect only mature fibrils may miss early or atypical infections.

Maternal immune activation provides a further dimension of host-pathogen interaction. Epidemiological and animal model evidence indicates that maternal infection can program long-term neurochemical and behavioral abnormalities in offspring, with microglial priming proposed as the mechanistic link. This research, primarily conducted in rodent models, suggests that the consequences of infectious disease in pregnant animals may extend beyond the acute infection to affect the neurodevelopment of offspring across multiple species.

Surveillance and Early Detection Principles

Detection of emerging disease requires surveillance systems designed to identify unusual patterns before they become epidemics. Passive surveillance, which relies on clinicians reporting unusual cases, is limited by underreporting and diagnostic delay. Active surveillance targets specific populations or pathogens and provides more reliable incidence data, but requires sustained resources and clear case definitions.

Risk-based surveillance concentrates sampling effort where emergence probability is highest: wildlife-domestic animal interfaces, live animal markets, and regions undergoing rapid land use change. Molecular diagnostics have transformed this work by enabling pathogen detection without prior culture, and genotypic classification has revised the taxonomy of several pathogen groups, including leptospires. The development of simpler, rapid assays has been driven by the recognition that early diagnosis improves clinical outcomes and that point-of-care testing expands surveillance capacity in resource-limited settings.

The World Organization for Animal Health publishes terrestrial animal health standards that define surveillance requirements and trade-related disease control measures. These standards provide the international framework within which national veterinary services operate, and they specify notification obligations for listed diseases. The World Health Organization and the Centers for Disease Control and Prevention publish complementary One Health frameworks that link veterinary surveillance to human health monitoring, recognizing that zoonotic emergence cannot be managed within a single sector.

Diagnostic Investigation of Suspected Emerging Pathogens

The diagnostic approach to a suspected emerging pathogen differs from routine clinical workup in several important ways. Standard panels target known endemic agents and may miss novel organizms, while reference laboratory algorithms often require specific clinical suspicion before appropriate testing is initiated. The clinician must therefore maintain a structured, hypothesis-driven sequence that accounts for host species, exposure history, and clinical syndrome.

Initial assessment should begin with a thorough signalment and epidemiologic history. Key questions include recent movement or introduction of animals, contact with wildlife or feral populations, attendance at exhibitions or sales, changes in feed or water sources, and vector exposure. For production species, inquiry into neighboring operations and shared equipment or personnel is essential. For companion animals, travel history and dietary items, particularly raw or undercooked products, carry significant weight. The global epidemiology of Campylobacter infection illustrates how consumption of animal products, water, and contact with animals constitute major transmission routes, and similar exposure categories apply broadly across emerging zoonoses.

Clinical sampling should be guided by the predominant organ system affected. Acute febrile illness with icterus, renal dysfunction, or reproductive failure warrants paired acute and convalescent serology alongside molecular testing on blood, urine, or tissues. The review of leptospirosis epidemiology emphasizes that simpler rapid assays have been developed largely because early antibiotic therapy improves outcomes in acute disease, yet these assays vary in sensitivity depending on stage of infection. Molecular diagnosis and typing have modified the clinical and epidemiological value of laboratory confirmation, but interpretation requires knowledge of vaccination status and regional serovar distribution.

Interpretation of results must account for the possibility of co-infection. A positive test for one agent does not exclude a second emerging pathogen, particularly in animals with outdoor access or complex management histories. Conversely, detection of a known commensal organizm does not establish causation. The diagnostic sequence should therefore include a defined decision point: if initial targeted testing is negative and clinical signs persist or cluster epidemiologically, escalation to broader methods such as metagenomic sequencing or referral to a veterinary diagnostic laboratory with specialized capacity is warranted.

Risk Stratification and Triage

Once a potential emerging pathogen is identified or strongly suspected, the clinician must determine the urgency of response. This assessment drives decisions about isolation, reporting, treatment, and notification of public health authorities. A structured risk stratification approach considers transmissibility, zoonotic potential, severity of disease, and availability of control measures.

Transmissibility should be assessed by the suspected route of spread. Respiratory pathogens generally require more aggressive isolation than those transmitted by direct contact or fomites. Zoonotic potential requires immediate consideration of human health risks, particularly for immunocompromised household members or agricultural workers. The WHO One Health framework explicitly links human, animal, and environmental health for zoonotic disease control, and the CDC zoonotic disease resources provide guidance on cross-sector collaboration and disease prioritization.

High-risk presentations include acute febrile illness with hemorrhagic signs, unexplained neurologic disease, abortion storms, or sudden death clusters in multiple animals. These presentations warrant immediate isolation of affected animals, use of personal protective equipment, and consultation with state or provincial veterinary authorities. Moderate-risk presentations include diarrhea, respiratory disease, or dermatitis in animals with known exposure to wildlife or high-density production settings. Low-risk presentations involve sporadic disease with no epidemiologic linkage or zoonotic concern.

The decision to report a suspected emerging disease to authorities should be made early instead of after laboratory confirmation. Most jurisdictions require reporting of specific diseases, and the list varies by region and species. The WOAH terrestrial animal health standards define international notification requirements for listed diseases, and clinicians should be familiar with the reporting obligations in their jurisdiction. When uncertainty exists about whether a condition is reportable, consultation with the relevant authority is appropriate.

Infection Control and Biocontainment

Infection control measures must be scaled to the risk assessment. For sporadic cases with low zoonotic potential, standard precautions may suffice. These include dedicated examination equipment, hand hygiene, and routine environmental disinfection. For high-risk pathogens, enhanced precautions are required: dedicated isolation housing, footbaths, disposable outerwear, and restriction of personnel movement.

The physical layout of the facility determines what is feasible. A mixed animal practice with separate small animal and large animal entrances can implement spatial separation more readily than a single-room ambulatory practice. In ambulatory settings, the vehicle itself becomes a fomite risk, and protocols for disinfection between farm visits are essential. Production species present additional challenges because isolation facilities may not exist on farm. In these situations, cohorting affected animals, designating dedicated equipment and personnel, and controlling visitor access become the primary containment strategies.

Environmental decontamination requires knowledge of the specific pathogen's susceptibility profile. Enveloped viruses are generally susceptible to routine disinfectants, while non-enveloped viruses, bacterial spores, and prions require progressively more aggressive protocols. The review of prion protein aggregation mechanisms notes that the infectious form of the prion protein differs from the neurotoxic species, and prion decontamination requires specialized procedures that exceed standard disinfection. For most emerging bacterial and viral pathogens, however, accelerated hydrogen peroxide or bleach-based products at appropriate concentrations are effective, and the MSD Veterinary Manual professional resources provide species-specific infection control guidance.

Treatment Considerations and Antimicrobial Stewardship

Empirical therapy should be initiated when clinical signs are severe or when delay is likely to worsen outcomes. The choice of antimicrobial class depends on the suspected pathogen, the species treated, and the route of administration feasible in the clinical setting. For suspected leptospirosis, early initiation of antibiotic therapy is important in acute disease, as noted in the leptospirosis review, and penicillin derivatives or doxycycline are commonly selected. Current formulary and label references must be consulted for species-specific doses, withdrawal periods, and contraindications.

Antimicrobial stewardship becomes particularly important when an emerging pathogen is suspected because empirical broad-spectrum therapy may mask clinical signs, delay definitive diagnosis, or select for resistance. The review of nanoantibiotics highlights that drug resistance enforces high-dose administration of conventional agents, often generating intolerable toxicity, and that nontraditional approaches are under investigation. For veterinary practice, the immediate priority is to collect appropriate diagnostic samples before initiating therapy, then narrow the antimicrobial spectrum once culture and susceptibility results are available.

Treatment decisions also depend on the production system. In food animals, withdrawal periods constrain therapeutic choices, and the economic cost of treatment must be weighed against the value of the animal and the risk of herd spread. In companion animals, owner preferences and the human-animal bond influence decisions, but zoonotic risk to household members must be clearly communicated. In wildlife rehabilitation settings, treatment may be limited by the goal of release, and euthanasia may be the most appropriate option for animals with poor prognosis or high zoonotic risk.

Documentation and Communication

Accurate documentation serves multiple purposes in emerging disease response. The medical record must capture the epidemiologic history, clinical findings, diagnostic samples collected, test results, treatment administered, and outcome. This information supports retrospective analysis, regulatory reporting, and epidemiologic investigation. Records should also document communication with owners, public health authorities, and diagnostic laboratories.

Communication with owners requires clear explanation of the zoonotic risk, the rationale for diagnostic testing, and the expected timeline for results. Owners should be advised on measures to reduce household transmission, including hand hygiene, restriction of animal contact for immunocompromised individuals, and safe handling of excreta. For production operations, communication extends to farm workers, who may require specific training on personal protective equipment and recognition of clinical signs in themselves or family members.

The AVMA practice resources provide guidance on professional communication and practice management that applies to emerging disease scenarios. Clinicians should also establish relationships with diagnostic laboratories and public health agencies before an outbreak occurs, so that the reporting pathway is familiar and efficient when time is critical.

Recognized Complications and Failure Modes

The most consequential failure in emerging disease response is delayed recognition of a novel pathogen because clinical signs mimic endemic disease. Leptospirosis illustrates this pattern. Its presentation overlaps with numerous febrile and hepatorenal conditions, and the diagnosis is frequently missed until outbreaks are established. The epidemiology has been modified by changes in animal husbandry, climate, and human behavior, which means historical incidence data may mislead the clinician assessing a current cluster Leptospirosis review. Early detection depends on maintaining a low threshold for diagnostic testing when multiple animals present with compatible signs and when known risk factors, such as flooding or recent livestock introduction, are present.

A second failure mode is over-attribution to a familiar pathogen without confirmatory testing. Campylobacteriosis in poultry flocks is often assumed to be a production issue instead of a zoonotic threat, yet the global incidence has increased across developed and developing regions, and emerging species such as Campylobacter concisus and Campylobacter ureolyticus are increasingly recognized as clinically important global epidemiology of Campylobacter infection. The corrective action is to submit samples for speciation and typing instead of relying on genus-level identification.

A third failure involves biocontainment breaches during sample handling or necropsy. Coronaviruses that crossed species barriers to cause SARS and MERS highlight how pathogen transmission can occur before clinical recognition in the index case coronavirus emergence review. Standard barrier precautions may be insufficient when the pathogen's route of transmission is unknown. The discriminating check is to treat all suspected emerging pathogens as high-consequence until ruled out, and to document the chain of custody for diagnostic specimens.

Common Errors in Clinical Reasoning

Less experienced clinicians often anchor on the most probable diagnosis and fail to revise when treatment fails. The corrective action is to establish a predetermined re-evaluation point, typically 48 to 72 hours after initiating therapy, at which response is formally assessed. If the animal has not improved, the differential list must be expanded instead of repeating the same diagnostic tests.

A second error is conflating detection with characterization. Identifying a pathogen by point-of-care assay does not establish its zoonotic potential, virulence, or transmission dynamics. The molecular basis of host affinity varies across species, and receptor compatibility cannot be inferred from clinical presentation alone coronavirus host receptor analysis. Confirmatory characterization at a reference laboratory is required before risk communication.

A third error is neglecting environmental sampling. Many emerging pathogens persist in water, soil, or fomites, and failure to identify the environmental reservoir guarantees recurrence. Leptospirosis transmission is heavily influenced by environmental conditions, and control measures that ignore the environmental component are likely to fail Leptospirosis review.

Limitations of Current Evidence

The evidence base for emerging disease response is uneven. Most published data derive from retrospective outbreak analyzes, which are subject to reporting bias and cannot establish causal relationships. Experimental animal models for coronaviruses have improved, but reproducible models that recapitulate natural pathogenesis across species remain an active research need coronavirus animal model limitations.

Expert opinion differs on several practical points. The threshold for initiating empirical antimicrobial therapy in suspected emerging bacterial infections is contested, particularly when treatment may select for resistance. The role of immunomodulatory therapy in viral infections of animals is similarly debated, with evidence drawn largely from human medicine and extrapolated across species. The MSD Veterinary Manual professional edition provides species-specific guidance, but clinicians should recognize that recommendations for novel pathogens are often based on analogy instead of direct evidence.

Surveillance data are biased toward notifiable diseases and commercially important species. Wildlife reservoirs are under-sampled, and the absence of detection should not be interpreted as absence of circulation. International standards for surveillance and trade-related disease control are published by the World Organization for Animal Health, but their application varies by region and production system WOAH terrestrial animal health standards.

Escalation and Referral Criteria

Referral to a specialist or reference laboratory is warranted when any of the following apply: the pathogen cannot be identified by routine diagnostics, the clinical presentation suggests a novel syndrome, the outbreak involves multiple species, or the condition has zoonotic potential that exceeds local diagnostic capacity. Molecular typing and whole-genome sequencing should be performed at a reference laboratory instead of attempted in practice settings without validated protocols.

Regulatory reporting obligations vary by jurisdiction and by pathogen. The clinician should consult national and international reporting requirements before communicating findings publicly. The CDC One Health resources and the WHO One Health framework provide guidance on cross-sector collaboration and notification pathways. When in doubt, report to the relevant authority and document the consultation.

Specialist consultation is also indicated when infection control measures fail to contain spread despite correct implementation. This suggests either a breakdown in protocol execution or an unrecognised transmission route, and both possibilities require external review. The AVMA practice resources offer guidance on biosecurity and professional obligations, but they do not replace direct consultation with an epidemiologist or veterinary public health specialist.

Frequently Asked Questions

How Should a Practice Prioritize Emerging Disease Investigations When Diagnostic and Biocontainment Resources Are Limited?

When advanced diagnostics are unavailable, prioritize based on clinical presentation, exposure history, and epidemiological plausibility. Begin with rapid, in-house screening for common endemic pathogens that mimic emerging diseases, then escalate to reference laboratories for pathogen identification and molecular typing when the clinical picture remains unexplained. The MSD Veterinary Manual professional edition provides species-specific guidance on differential diagnosis and sample handling that supports this staged approach. For biocontainment, implement practical measures such as dedicated examination rooms, personal protective equipment appropriate to the suspected transmission route, and restricted staff movement. The CDC One Health and zoonotic disease resources offer tiered infection control recommendations that scale to available infrastructure. Document all limitations in the medical record so that diagnostic interpretation accounts for reduced sensitivity or specificity.

What Records Should Be Kept During an Emerging Disease Investigation, and for How Long?

Maintain a chronological investigation log that includes signalment, clinical signs, chronologic progression, treatments administered, sample collection dates and sites, laboratory submission forms, and all communication with diagnostic laboratories and regulatory authorities. Record biosecurity measures implemented and staff exposures. The WOAH terrestrial animal health code specifies notification and record-keeping expectations for reportable diseases, and these records should be retained according to jurisdictional requirements, typically several years beyond the case resolution. Photographic documentation of lesions and gross pathology is valuable for retrospective review and peer consultation. Ensure that records distinguish confirmed findings from suspected or rule-out diagnoses. This distinction becomes critical if the case is later revisited during an outbreak investigation or legal proceeding.

How Does the Diagnostic Approach Change When Investigating Wildlife Versus Domestic Animal Cases?

Wildlife investigations require additional consideration of capture stress, sample quality, and the absence of reliable clinical history. Antemortem sampling may be limited to blood, swabs, and feces, whereas postmortem examination often provides the definitive diagnosis. Species-specific reference intervals for hematology and biochemistry are frequently unavailable, so interpretation should emphasize pathogen detection over biomarker changes. The MSD Veterinary Manual professional edition notes that many infectious agents behave differently across host species, and a pathogen that is incidental in one species may be fatal in another. Coordinate with wildlife agencies early, as they may have established protocols for sample submission and disease reporting. For zoonotic pathogens, additional precautions are warranted because wildlife handlers and necropsy personnel face exposure risks that differ from domestic animal practice.

What Should I Communicate to a Client When a Zoonotic Pathogen Is Suspected?

Communicate clearly and without alarming language, focusing on concrete precautions instead of speculative outcomes. Explain the suspected pathogen, the basis for that suspicion, and the specific steps the client should take to protect household members and other animals. The WHO One Health initiative emphasizes that zoonotic disease control requires coordinated action across human and animal health sectors, so advise the client to inform their physician or public health authority if they develop compatible symptoms. Provide written instructions covering hygiene, isolation of affected animals, and safe disposal of waste. Document the conversation in the medical record, including the client's acknowledgement of the information provided. If the pathogen is reportable, explain that you are required to notify the relevant authority and that this is a standard public health measure.

How Should I Discuss a Suspected Emerging Disease with a Practice Owner or Supervisor?

Present the clinical findings, the differential diagnosis, and the specific reasons an emerging pathogen is being considered. Distinguish between findings that are consistent with a known endemic disease and those that are atypical or unexplained. Reference the AVMA practice resources for guidance on professional obligations and practice protocols. Propose a concrete action plan that includes diagnostic testing, biosecurity measures, and a timeline for reassessment. Estimate costs and resource requirements so the practice owner can make an informed decision. If regulatory notification may be required, state this explicitly and identify the relevant authority. Frame the discussion around patient welfare, staff safety, and practice liability, which are the concerns most likely to influence administrative decisions.

What Are the Practical Limits of Point-of-Care Testing for Emerging Pathogens?

Point-of-care tests are designed for specific known targets and will not detect novel or unexpected pathogens. A negative result does not exclude infection, particularly early in the disease course when pathogen load may be below the detection threshold. The MSD Veterinary Manual professional edition advises that test sensitivity and specificity vary by assay, sample type, and disease stage, and that results should be interpreted in the context of clinical signs and exposure history. Confirmatory testing at a reference laboratory is required when point-of-care results conflict with clinical observations or when the case has public health implications. Molecular assays such as PCR offer improved sensitivity but require appropriate sample handling and may not be available for emerging agents until primers are developed.

Related Clinical & Scientific Guides

• Wildlife Disease Surveillance: Designing and Implementing a One Health Program
• Biosecurity Risk Assessment for Livestock Operations: A Practical Framework
• Rabies Post-Exposure Prophylaxis in Veterinary Personnel

References and Further Reading

• Leptospirosis.. 2001.
• Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.. 2003.
• Global Epidemiology of Campylobacter Infection.. 2015.
• "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era.. 2011.
• From SARS to MERS, Thrusting Coronaviruses into the Spotlight.. 2019.
• Maternal immune activation and abnormal brain development across CNS disorders.. 2014.
• WHO One Health Initiative. WHO.
• CDC One Health and Zoonotic Disease Resources. CDC.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• One Health Approach to Emerging Zoonoses: Integrating Veterinary and Human Health Data
• Antimicrobial Resistance Surveillance in Food Animals: Sampling Strategies and Data Interpretation
• Antimicrobial Resistance Surveillance in Wildlife: Methods and Gaps
• Antimicrobial Resistance in Wildlife: Environmental Reservoir and Public Health Risk
• Antimicrobial Stewardship in Food Animal Practice: Metrics and Benchmarks

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.